Page 3 - NIH/National Institute of Allergy and Infectious Diseases

Medical research

The potential and challenges of mucosal COVID-19 vaccines

In November 2022, the National Institute of Allergy and Infectious Diseases (NIAID) co-hosted a virtual workshop on the importance and challenges of developing mucosal vaccines for SARS-COV-2. The highlights of this workshop ...

Diseases, Conditions, Syndromes

Experimental NIH Sudan virus vaccine protects macaques

A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. ...

Diseases, Conditions, Syndromes

Marburg virus vaccine shows promising results in first-in-human study

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers ...

Medical research

Probiotic markedly reduces S. Aureus colonization in phase 2 trial

A promising approach to control Staphylococcus aureus bacterial colonization in people—using a probiotic instead of antibiotics—was safe and highly effective in a Phase 2 clinical trial. The new study, reported in The ...

page 3 from 40